Orchestra BioMed Holdings, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2025 Annual Meeting of Stockholders held on June 24, 2025. The Company is an emerging growth company incorporated in Delaware, with its common stock trading on the Nasdaq Global Market under the symbol OBIO.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
As of the record date (April 28, 2025), 38,312,512 shares were entitled to vote. A total of 28,177,159 shares were represented at the meeting. Stockholders approved two proposals:
- Proposal 1: Election of Directors
- Chris Cleary: Elected with 24,555,860 votes for, 64,650 withheld, and 3,556,649 broker non-votes.
- Pamela Connealy: Elected with 23,674,360 votes for, 946,150 withheld, and 3,556,649 broker non-votes.
- David Pacitti: Elected with 24,227,123 votes for, 393,387 withheld, and 3,556,649 broker non-votes.
- All three nominees were elected as Class II directors to serve until the 2028 annual meeting.
- Proposal 2: Ratification of Auditor
- The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was approved.
- Votes: 28,140,709 For, 34,087 Against, 2,363 Abstentions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the definitive proxy statement filed on April 30, 2025, for detailed biographies of the elected directors and the rationale for the auditor selection.
- Confirm the total number of shares outstanding and the percentage of ownership represented by the 28,177,159 shares voted.
- Review the Company's upcoming fiscal year 2025 financial reports for the first time since the auditor ratification.